Cite
HARVARD Citation
Borthakur, G. et al. (2021). BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study. Cancer. 127 (8), pp. 1246-1259. [Online].